Related references
Note: Only part of the references are listed.Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2018)
Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
Daisuke Matsutani et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus Mechanistic Links, Clinical Data, and Future Directions
Shilpa Vijayakumar et al.
CIRCULATION (2018)
Heart Disease and Stroke Statistics-2018 Update A Report From the American Heart Association
Emelia J. Benjamin et al.
CIRCULATION (2018)
Sotagliflozin: a dual sodium-glucose co-transporter-1 and-2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus
H. Sims et al.
DIABETIC MEDICINE (2018)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
Hussein Al Jobori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Pharmacotherapy of type 2 diabetes: An update
Jagriti Upadhyay et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
Elisabetta Patorno et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
Elisabetta Patorno et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
Sam Miller et al.
DIABETES THERAPY (2018)
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
Sam Miller et al.
DIABETES THERAPY (2018)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner et al.
CIRCULATION (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Julio Rosenstock et al.
DIABETES OBESITY & METABOLISM (2018)
Glycemic Targets: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Ralph A. DeFronzo et al.
NATURE REVIEWS NEPHROLOGY (2017)
Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study
Yen-Chieh Lee et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Novel Diabetes Drugs and the Cardiovascular Specialist
Naveed Sattar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
James L. Januzzi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
Christianne L. Roumie et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System
Gian Paolo Fadini et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure
Milton Packer
CIRCULATION (2017)
Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes
Anna Solini et al.
DIABETES OBESITY & METABOLISM (2017)
Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects
Nahoko Kasahara-Ito et al.
DRUG RESEARCH (2017)
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone
Steven G. Terra et al.
DIABETES OBESITY & METABOLISM (2017)
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
Javad Habibi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure
Genjiro Kimura
CIRCULATION JOURNAL (2016)
Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update
Aleksandra Novikov et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
Francois Briand et al.
DIABETES (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Nikolaus Marx et al.
EUROPEAN HEART JOURNAL (2016)
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
Tushar Madaan et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
Sylvie Erpeldinger et al.
BMC ENDOCRINE DISORDERS (2016)
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Giulia Ferrannini et al.
DIABETES CARE (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2015)
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Aurora Merovci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review
Varun Vaidya et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2015)
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
Greg Fulcher et al.
DIABETES THERAPY (2015)
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
Greg Fulcher et al.
DIABETES THERAPY (2015)
Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
Bruce Neal et al.
DIABETES CARE (2015)
Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study
Ulrik M. Mogensen et al.
DIABETOLOGIA (2015)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin
Takeshi Kadokura et al.
CLINICAL PHARMACOKINETICS (2014)
Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Serge A. Jabbour et al.
DIABETES CARE (2014)
SGLT2 inhibitors in the treatment of type 2 diabetes
Farhad M. Hasan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Ketone body metabolism and cardiovascular disease
David G. Cotter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2013)
Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure Systematic Review of Observational Studies Involving 34 000 Patients
Dean T. Eurich et al.
CIRCULATION-HEART FAILURE (2013)
Cardiac Insulin-Resistance and Decreased Mitochondrial Energy Production Precede the Development of Systolic Heart Failure After Pressure-Overload Hypertrophy
Liyan Zhang et al.
CIRCULATION-HEART FAILURE (2013)
Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
Muhammad A. Abdul-Ghani et al.
DIABETES (2013)
Diabetes Care: State of the Union
William T. Cefalu
DIABETES CARE (2013)
Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion Results of a randomized, placebo-controlled study
David Polidori et al.
DIABETES CARE (2013)
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo et al.
DIABETES CARE (2013)
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
Guntram Schernthaner et al.
DIABETES CARE (2013)
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
M. Nauck et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2013)
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
F. J. Lavalle-Gonzalez et al.
DIABETOLOGIA (2013)
Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
David Polidori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Metformin: an old but still the best treatment for type 2 diabetes
Lilian Beatriz Aguayo Rojas et al.
DIABETOLOGY & METABOLIC SYNDROME (2013)
Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects
Zhuang Miao et al.
DRUG METABOLISM AND DISPOSITION (2013)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Jacob Lonborg et al.
EUROPEAN HEART JOURNAL (2012)
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
R. R. Henry et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ele Ferrannini et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
S. Sha et al.
DIABETES OBESITY & METABOLISM (2011)
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
Steven E. Nissen et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
Michel Komajda et al.
EUROPEAN HEART JOURNAL (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Leo Timmers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels:: Involvement of hepatocyte nuclear factor-1α expression and activity
H. S. Freitas et al.
ENDOCRINOLOGY (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
LA Nikolaidis et al.
CIRCULATION (2004)
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
M Hanefeld et al.
EUROPEAN HEART JOURNAL (2004)
Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes - A retrospective cohort study
TE Delea et al.
DIABETES CARE (2003)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
